AppLovin 3Q26 Business Update: No Notes
AppLovin’s Q3 revenue rose 55% year over year as AXON model gains expanded margins, while ad take-rate compression remains the key competitive risk.
AppLovin’s Q3 revenue rose 55% year over year as AXON model gains expanded margins, while ad take-rate compression remains the key competitive risk.
Thought there was ample supply still parked on balance sheet in April $NVDA @eliav https://t.co/SaEkbWG311 https://t.co/4ffaSSMwXH
As #copper industry execs talk of the greatest trade they've ever seen, its interesting to see that my recently published Euro-listed copper idea is the top performing name in the sector since I published it, alongside $FCX, --> $NDA $NDA.GR 👇 https://t.co/3kyp2k7VWl https://t.co/Kjp3Hlssgb
(Late) Q2'25 Update New: $META, $STN.TO, $FTT.TO, $CVG.TO, $GDI.TO, $VCI.V, $IOT.V Sold: $KNSL, $CJT.TO, $RPI.UN, $MRD.TO, $HMM.A, $FORA.TO, $THNC.TO, $BRM.V Q2: 6.6% vs 10.6% for SPX ITD (Jan '21): +165% vs +68% Fairly happy with how the portfolio is positioned 👇 https://t.co/FPQbbegoEQ
3/ $RICK $PAR $APG $GFL $TIC
Value Sits name $BG up another +6% today, as market starts to price in the transformative #Viterra acquisition.. https://t.co/SsAL2gOw6A https://t.co/wwN5ZUrkYz
Another positive update for the Value Sits Model portfolio with the news that the $BG acquisition of #Viterra has received approval in China; $BG up +7% today, while mkt down- another example of benefits of idiosyncratic/event situations https://t.co/p76gcFbQBu
Silver breaking out finally. Long $SLV calls ... not a recommendation :) https://t.co/AFPUTa6n4P
Uber's Q3 growth, margin expansion and rising cash flow clash with a bear-case valuation as investors price in robotaxi disruption risk…
Amazon’s AWS grew 39.3% with roughly 39% margins, while retail unit growth and lower cost to serve expand its delivery network’s reach.
Intel's Q3 2026 results were hit by memory costs and an Israel shutdown, but enterprise AI inference could lift CPU demand as server…
Telkom Indonesia trades at 9x earnings and an 11% yield as MSCI-driven selling obscures telecom consolidation, price increases and…
Florida marinas are 92% full as boat counts rise and permits constrain new supply, creating pricing power for existing operators such as…
Delta Air Lines' premium, loyalty and ancillary businesses generate 61% of revenue as cash flow supports debt reduction despite fuel and…
Microsoft rose 6.7% to a $555.80 record after Q1 FY27, with profitable growth and free cash flow reinforcing investor confidence in its AI…
Moderna’s Phase 3 melanoma regimen cut relapse or death 42%, but persistent cash burn and limited launches leave its $220.83 share price…
GPC’s NAPA commercial sales grew 4% in Q3, trailing AutoZone and O’Reilly as freight, fuel and rent cut North American Automotive margins…
AMSC and Datadog will be fine, while SiTime is worth a closer look.
Intuit CEO Sasan Goodarzi discusses using AI to turn accountants from customer-acquisition partners into customers, alongside QuickBooks,…
DigitalOcean reported Q3 revenue up 40% to $321 million and lifted Q4 guidance above consensus, while GPU and data-center expansion cut…
Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…
L3Harris booked $19.3 billion of Q3 orders, lifting backlog to $53.2 billion, raised FY26 guidance and cut its 2028 free-cash-flow target…
Coupang’s product-commerce growth rose 9% as data-leak effects fade, while management expects margins to return to pre-incident levels by…
David Orr describes running Militia Capital’s roughly 500-stock long-short portfolio, using expected value, correlation and factor…
Coupang expects Product Commerce margins to return to pre-data incident levels by mid-2027 as customer spending recovers and Taiwan…
Novo Nordisk beat Q3 consensus as Wegovy pill sales reached DKK 5.4bn, raised 2026 guidance again and reported DKK 79.2bn revenue.
Shopify's 3Q 2026 GMV grew 30% FX-neutral, reaching 46% of Amazon retail GMV after merchants captured nearly half of incremental U.S.
Eli Lilly uses AI-driven drug discovery and its research scale to accelerate molecule development and broaden its product pipeline.
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.